GLP Research — The 4 compounds being studied.
GLPs are a family of compounds studied in clinical research for metabolic regulation. Researchers are currently studying 4 main ones.
What is this page about?
Retatrutide
Triple agonist studied for GIP + GLP-1 + Glucagon receptor activity.
Tirzepatide
Dual agonist studied for GIP + GLP-1 receptor activity. FDA approved for type 2 diabetes and obesity under brand names Mounjaro / Zepbound.
Cagrilintide
Long-acting amylin analog studied in combination as CagriSema.
Semaglutide
Single GLP-1 agonist studied in trials and approved as Ozempic / Wegovy.
What did the trials report?
Retatrutide
Phase 2 NEJM 2023 reported 24.2% body weight change over 48 weeks at 12mg dose in trial participants. Phase 3 TRIUMPH trials are ongoing.
Tirzepatide
Phase 3 SURMOUNT-1 reported 22.5% mean body weight change over 72 weeks at 15mg dose.
Cagrilintide + Semaglutide
CagriSema Phase 2 reported 15.6% weight change over 32 weeks. Phase 3 REDEFINE program is ongoing.
All compounds are supplied for laboratory research only.